Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate vs atomoxetine effects on emotional intelligence, executive function and self-efficacy in adolescents with ADHD
IRCT20160523028008N31Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of methylphenidate and atomoxetine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Change in emotional intelligence, Change in executive function and 1 more. Started Feb 2024; status: completed.
02
Drugs
methylphenidateatomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on IRCT20160523028008N31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160523028008N31.